Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Drug Delivery

Rational design of inhaled antibacterials targeting alveolar macrophages for efficient killing of resistant bacteria associated with lower respiratory tract infections (LRTIs)

5 affiliations
  1. 1Pharmacy Discipline, School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia
  2. 2Centre for Immunology and Infection Control (CIIC), Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia
  3. 3School of Chemistry and Physics, Faculty of Science, Queensland University of Technology, Brisbane, QLD, Australia
  4. 4School of Medicine and Dentistry & Institute for Biomedicine and Glycomics, Griffith University, Gold Coast Campus, QLD, Australia
  5. 5Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia

Abstract

Lower respiratory tract infections (LRTIs), caused by antibiotic-resistant bacteria, are a leading cause of global death and morbidity. One of the principal limitations in treating respiratory bacterial infections is inefficient delivery and appropriate therapeutic drug concentrations to infected cells, as required to kill resistant bacteria. Inhaled antibiotic delivery technology specifically delivers antibacterials directly into the infected cells of the lungs and provides the required therapeutic concentration at a very low delivered dose, with a greatly reduced risk of systemic adverse effects. An alveolar macrophage (AM)-targeted antibiotic delivery strategy utilizing receptor-ligand interactions or stimuli-responsive mechanisms of drug release demonstrated efficient killing of intracellular bacteria. The rational design of antibacterials or formulations for inhalation is the key to achieving this goal. Based on ligand chemistry, decorating antibiotic carriers with ligands that target specific AM receptors is a novel strategy to ensure precise antibiotic delivery to the site of infection while reducing both the side effects associated with high systemic doses and the risk of further promoting antibiotic resistance. This review highlights advances in AM-targeted inhaled antibacterials, identification of appropriate ligands for specific AM receptors, mechanisms of interaction, and subsequent release of antibiotics through carrier degradation, pH-responsive behavior, or enzymatic cleavage to eradicate resistant bacteria. Finally, we discuss the ongoing challenges and future directions for AM-targeted inhaled antibacterials against LRTIs.

Related

  1. Tumor-associated macrophages beyond M1/M2 in NSCLC: spatially organized programs, therapy resistance, and translational targeting
    Xiao-Long Wang, Ziheng Jiang, Qianqian Lu +1
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  2. Single-cell RNA Sequencing Analysis Reveals That Targeting PLG–PLGRKT Signaling-mediated Pro-fibrotic Scar-associated Macrophages Ameliorates Liver Fibrosis in Biliary Atresia
    Xin Li, Tengfei Li, Shaowen Liu +9
    Journal of Clinical and Translational HepatologyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  3. Factors associated with discharge on higher respiratory support for children with tracheostomy hospitalized with bacterial tracheostomy‐associated infections: A prospective, multicenter cohort study
    Krystal S. Jin, Naoko Kono, Jonathan D. Cogen +11
    Journal of Hospital MedicinePeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  4. Respiratory Viral Positivity Is Associated with Decreased Risk of Serious Bacterial Infections in Febrile Infants.
    Diormi A Rosario, Anum Mitha, Jessica Zerzan +6
    The western journal of emergency medicinePeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  5. The H3K27me3-NR1D1-IFN-γ axis in trained macrophages induced by early respiratory virus infection drives non-T2 asthma in children
    Hanglin Li, Boyang Zheng, Beibei Qin +14
    Cellular and Molecular ImmunologyPeer-reviewedLicence not statedFull textPhysiologyPMC
BibTeX
@article{islam2026rational,
  title = {{Rational design of inhaled antibacterials targeting alveolar macrophages for efficient killing of resistant bacteria associated with lower respiratory tract infections (LRTIs)}},
  author = {Nazrul Islam and Emad L. Izake and Kirsten Spann and Yin Xiao and Timothy J. Wells},
  journal = {Drug Delivery},
  year = {2026},
  month = nov,
  doi = {10.1080/10717544.2026.2752706},
  url = {https://doi.org/10.1080/10717544.2026.2752706},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Rational design of inhaled antibacterials targeting alveolar macrophages for efficient killing of resistant bacteria associated with lower respiratory tract infections (LRTIs)
AU  - Nazrul Islam
AU  - Emad L. Izake
AU  - Kirsten Spann
AU  - Yin Xiao
AU  - Timothy J. Wells
PY  - 2026
DA  - 2026/11/03
JO  - Drug Delivery
DO  - 10.1080/10717544.2026.2752706
UR  - https://doi.org/10.1080/10717544.2026.2752706
AB  - Lower respiratory tract infections (LRTIs), caused by antibiotic-resistant bacteria, are a leading cause of global death and morbidity. One of the principal limitations in treating respiratory bacterial infections is inefficient delivery and appropriate therapeutic drug concentrations to infected cells, as required to kill resistant bacteria. Inhaled antibiotic delivery technology specifically delivers antibacterials directly into the infected cells of the lungs and provides the required therapeutic concentration at a very low delivered dose, with a greatly reduced risk of systemic adverse effects. An alveolar macrophage (AM)-targeted antibiotic delivery strategy utilizing receptor-ligand interactions or stimuli-responsive mechanisms of drug release demonstrated efficient killing of intracellular bacteria. The rational design of antibacterials or formulations for inhalation is the key to achieving this goal. Based on ligand chemistry, decorating antibiotic carriers with ligands that target specific AM receptors is a novel strategy to ensure precise antibiotic delivery to the site of infection while reducing both the side effects associated with high systemic doses and the risk of further promoting antibiotic resistance. This review highlights advances in AM-targeted inhaled antibacterials, identification of appropriate ligands for specific AM receptors, mechanisms of interaction, and subsequent release of antibiotics through carrier degradation, pH-responsive behavior, or enzymatic cleavage to eradicate resistant bacteria. Finally, we discuss the ongoing challenges and future directions for AM-targeted inhaled antibacterials against LRTIs.
SN  - 1071-7544
SN  - 1521-0464
ER  -